Business Description
DMK Pharmaceuticals Corp
NAICS : 325412
SIC : 2834
ISIN : US00547W2089
Description
DMK Pharmaceuticals Corp is a specialty pharmaceutical company focused on developing and commercializing products for emergency and acute care settings. Its commercial product is SYMJEPI (epinephrine) injection in 0.3 mg and 0.15 mg doses, a pre-filled syringe for the emergency treatment of acute allergic reactions, including anaphylaxis. The company has also developed ZIMHI, a high-dose naloxone injection for the treatment of opioid overdose. Its pipeline has included investigational candidates such as tempol and a beclomethasone metered-dose inhaler. DMK Pharmaceuticals targets hospitals, emergency departments, first responders, and other healthcare providers in the United States, generating revenue primarily through product sales and related commercial partnerships. The company was formerly known as Adamis Pharmaceuticals Corporation before changing its name.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
DMK Pharmaceuticals Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3.402 | ||
| EPS (TTM) (€) | -8.928 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -0.7 | ||
| 3-Year Sortino Ratio | -0.69 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 3.255 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 3.255 - 3.255 | ||
| Shares Outstanding (Mil) | 10.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
DMK Pharmaceuticals Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
DMK Pharmaceuticals Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-16 | In 55 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 | -- | ||
| Second quarter earnings results for 2026 | 2026-08-14 | -- | ||
| First quarter earnings conference call for 2026 | 2026-05-22 | -- | ||
| First quarter earnings results for 2026 | 2026-05-22 | -- | ||
| Fourth quarter earnings conference call for 2025 | 2026-04-13 17:00 | -- | ||
| Annual report for 2025 | 2026-04-13 | -- | ||
| Fourth quarter earnings results for 2025 | 2026-04-13 | -- | ||
| Annual report for 2025 | 2026-03-16 | -- | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-23 17:00 | -- |
Show
Entries
DMK Pharmaceuticals Corp Frequently Asked Questions
What is DMK Pharmaceuticals Corp(STU:CY3)'s stock price today?
The current price of STU:CY3 is €3.26. The 52 week high of STU:CY3 is €3.26 and 52 week low is €3.26.
When is next earnings date of DMK Pharmaceuticals Corp(STU:CY3)?
The next earnings date of DMK Pharmaceuticals Corp(STU:CY3) is 2026-11-16 Est..
Does DMK Pharmaceuticals Corp(STU:CY3) pay dividends? If so, how much?
DMK Pharmaceuticals Corp(STU:CY3) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers